Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
Quisinostat besides its own efficacy, which can potentially lead to better results of
polychemotherapy and increase the mean time to progression, it may be demonstrated that
Quisinostat leads to sustained tumor sensitivity to platinum drugs. In this study safety and
tolerability of multiple administrations of Quisinostat in doses ranging from 8 mg to 12 mg
combined with standard backbone chemotherapy in patients with non-small cell lung cancer
(second line) and ovarian cancer (second and subsequent lines) will be investigated.